

Invitation to commentary regarding rights issue

Nanexa AB (publ) invites to a live commentary on the announced rights issue.

The live commentary and interview with CEO David Westberg will be held on Monday, September 25 at 10:00 am via Infront Direkt Studios, and viewers will have the opportunity to ask questions via chat.

The broadcast can be viewed at [this link](#).

The commentary will also be posted on Nanexa's website afterwards.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Invitation to commentary regarding rights issue](#)